EDIT Stock Analysis: Buy, Sell, or Hold?
EDIT - Editas Medicine, Inc. Common Stock
$2.47
0.24 (10.76%)
▲
5d:
+9.78%
30d:
+14.88%
90d:
+17.62%
BUY
MODERATE Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: May 11, 2026
Smart Money Accumulation
EDIT is down 7.1% this week, but smart money is accumulating calls. Top strike: $2.5 2026-05-15 with 1,180 OI. Call ratio: 92% View Scanner →
Strength: 7.7/10
Get Alerted When EDIT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: EDIT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: EDIT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: EDIT is currently trading at $2.47, which is considered slightly high relative to its 30-day fair value range of $2.05 to $2.48.
Technical Outlook: Technically, EDIT is in a strong uptrend. The price is approaching resistance at $2.49. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.8% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+146.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EDIT is in a strong uptrend. The price is approaching resistance at $2.49. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.8% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+146.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$2.05 -
$2.48
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.1%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.8%)
- BULLISH: Trading 146.6% below Wall St target ($5.50)
Fair Price Analysis
30-Day Fair Range
$2.05 -
$2.48
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.13
Resistance Level
$2.49
Current Trend
Strong Uptrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.55
Wall Street Target
$5.50
(+146.6%)
Revenue Growth (YoY)
-19.2%
Share & Embed Analysis
Last updated: March 31, 2026 3:02 PM ET
Data refreshes hourly during market hours. Next update: 4:02 PM
Data refreshes hourly during market hours. Next update: 4:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDIT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Amy Parison
SELL
474 shares
2026-03-03
Gilmore Neil O'neill
SELL
5394 shares
2026-03-03
Linda Burkly
SELL
749 shares
2026-03-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 57 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 59 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 43 HOLD |
